{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T16:40:36Z","timestamp":1769877636705,"version":"3.49.0"},"reference-count":53,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,1,2]],"date-time":"2013-01-02T00:00:00Z","timestamp":1357084800000},"content-version":"vor","delay-in-days":1274,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Andrology"],"published-print":{"date-parts":[[2009,7,8]]},"abstract":"<jats:p><jats:bold>ABSTRACT: <\/jats:bold> Peyronie's disease (PD) is a wound\u2010healing disorder in which a fibrotic plaque forms in the tunica albuginea layer of the penis. It clinically presents as any combination of penile pain, angulation, and erectile dysfunction. Recent studies indicate that PD has a prevalence of 3%\u20139% in adult men. Although the exact etiology has not been established, PD likely results from a predisposing genetic susceptibility combined with an inciting event such as microtrauma during intercourse. During the initial acute phase (6\u201318 months), the condition may progress, stabilize, or regress. For this reason authorities recommend a more conservative treatment approach, with a trial of oral and\/or intralesional pharmacotherapy, before surgical reconstruction is considered. Oral therapies most commonly employed include tocopherol (vitamin E) and paraaminobenzoate (Potaba), with colchicine, tamoxifen, propoleum, and acetyl\u2010<jats:sc>l<\/jats:sc>\u2010carnitine being used less often. There are a limited number of long\u2010term placebo\u2010controlled studies with these oral agents, and for the most part, studies have failed to show a consistent beneficial effect. Intralesional injection therapy for PD is more commonly used as a first\u2010line therapy. The current standard of care includes injection with interferon\u2010\u03b1\u20102b, verapamil, or collagenase. Interferon\u2010\u03b1\u20102b, in particular, has been documented in a large, multicenter, placebo\u2010controlled study to show significant benefit over placebo in decreasing penile curvature, plaque size, penile pain, and plaque density. However, intralesional interferon is associated with posttreatment flu\u2010like symptoms unless patients are premedicated with a nonsteroid anti\u2010inflammatory agent. Other available therapies that have not consistently shown efficacy in placebo\u2010controlled studies include corticosteroids, orgotein, radiation, and extracorporeal shockwave therapy. Surgery is considered when men with PD do not respond to conservative or medical therapy for approximately 1 year and cannot perform satisfactory sexual intercourse. Ongoing basic research in PD will likely identify future targets for medical exploitation.<\/jats:p>","DOI":"10.2164\/jandrol.108.006221","type":"journal-article","created":{"date-parts":[[2009,7,15]],"date-time":"2009-07-15T16:07:45Z","timestamp":1247674065000},"page":"397-405","source":"Crossref","is-referenced-by-count":50,"title":["Medical Management of Peyronie's Disease"],"prefix":"10.1002","volume":"30","author":[{"given":"Wayne J. G.","family":"Hellstrom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,1,2]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900414"},{"issue":"2","key":"e_1_2_4_3_1","first-page":"250","article-title":"Orgotein, a new drug for the treatment of Peyronie's disease","volume":"4","author":"Bartsch G.","year":"1981","journal-title":"Eur J Rheumatol Inflamm"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2007.00614.x"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02241.x"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2006.05969.x"},{"key":"e_1_2_4_7_1","first-page":"32","article-title":"Peyronie's disease; cortisone\u2010hyaluronidase\u2010hydrocortisone therapy","volume":"20","author":"Bodner H.","year":"1953","journal-title":"Trans West Sect Am Urol Assoc"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncpuro0409"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2003.04242.x"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000116450.82816.2c"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365599109024539"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2006.00417.x"},{"issue":"4","key":"e_1_2_4_13_1","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0022-5347(17)52339-3","article-title":"Topical beta\u2010aminopropionitrile in the treatment of Peyronie's disease","volume":"129","author":"Gelbard M.","year":"1983","journal-title":"J Urol"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(80)90028-X"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)39746-X"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)47123-0"},{"issue":"6","key":"e_1_2_4_17_1","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000473262","article-title":"Peyronie's disease: experience of local treatment with orgotein","volume":"7","author":"Gustafson H.","year":"1981","journal-title":"Eur Urol"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)45768-5"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-005-0867-8"},{"key":"e_1_2_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(06)00517-9"},{"key":"e_1_2_4_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1997.02849.x"},{"key":"e_1_2_4_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-4096.2001.02436.x"},{"key":"e_1_2_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900519"},{"key":"e_1_2_4_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042307-200411000-00015"},{"key":"e_1_2_4_25_1","first-page":"171","article-title":"Clinical evaluation of the use of propoleum in Peyronie's disease [in Spanish]","volume":"51","author":"Lemourt OM","year":"1998","journal-title":"Arch Esp Urol"},{"key":"e_1_2_4_26_1","first-page":"805","article-title":"Propoleum and Peyronie's disease [in Spanish]","volume":"56","author":"Lemourt OM","year":"2003","journal-title":"Arch Esp Urol"},{"key":"e_1_2_4_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000056153.47716.d0"},{"key":"e_1_2_4_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901083"},{"key":"e_1_2_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)35291-6"},{"key":"e_1_2_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64173-0"},{"key":"e_1_2_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(83)90197-8"},{"key":"e_1_2_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3900874"},{"key":"e_1_2_4_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000127744.18878.f1"},{"key":"e_1_2_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(06)00270-9"},{"key":"e_1_2_4_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02551115"},{"issue":"2","key":"e_1_2_4_36_1","first-page":"169","article-title":"Orgotein in the treatment of plastic induration of the penis (Peyronie's disease)","volume":"25","author":"Primus G.","year":"1993","journal-title":"Int Urol Nephrol"},{"key":"e_1_2_4_37_1","first-page":"41","article-title":"Controlled clinical trial of vitamin E in Peyronie's disease","volume":"9","author":"Pryor JP","year":"1983","journal-title":"Prog Reprod Biol"},{"key":"e_1_2_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.04.006"},{"key":"e_1_2_4_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1992.tb15836.x"},{"key":"e_1_2_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00700-0"},{"key":"e_1_2_4_41_1","first-page":"47","article-title":"La Peyronie's disease: our experience [in Italian]","volume":"45","author":"Revelli G.","year":"1990","journal-title":"Minerva Chir"},{"key":"e_1_2_4_42_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.11.5478"},{"key":"e_1_2_4_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1949.tb55300.x"},{"issue":"22","key":"e_1_2_4_44_1","first-page":"1085","article-title":"Orgotein iontophoresis in the therapy of induratio penis plastica [in Italian]","volume":"76","author":"Schieroni MP","year":"1985","journal-title":"Minerva Med"},{"key":"e_1_2_4_45_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-4096.2001.02436.x"},{"key":"e_1_2_4_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7262.2008.00351.x"},{"key":"e_1_2_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)68087-1"},{"key":"e_1_2_4_48_1","first-page":"347","volume-title":"Modern Nutrition in Health and Disease","author":"Traber MG","year":"1999"},{"key":"e_1_2_4_49_1","first-page":"813","article-title":"Mechanism of action of glucocorticoids: role of lipocortins [in French]","volume":"145","author":"Tranchant C.","year":"1989","journal-title":"Rev Neurol"},{"key":"e_1_2_4_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/pmj.79.934.449"},{"key":"e_1_2_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.12.022"},{"issue":"1","key":"e_1_2_4_52_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0022-5347(17)61894-9","article-title":"The natural history of Peyronie's disease","volume":"103","author":"Williams JL","year":"1970","journal-title":"J Urol"},{"issue":"6","key":"e_1_2_4_53_1","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0022-5347(17)67169-6","article-title":"Peyronie's disease: results with dermojet injection of dexamethasone","volume":"114","author":"Winter CC","year":"1975","journal-title":"J Urol"},{"key":"e_1_2_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)66108-1"}],"container-title":["Journal of Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.2164%2Fjandrol.108.006221","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.2164\/jandrol.108.006221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T14:03:43Z","timestamp":1697119423000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.2164\/jandrol.108.006221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,8]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,7,8]]}},"alternative-id":["10.2164\/jandrol.108.006221"],"URL":"https:\/\/doi.org\/10.2164\/jandrol.108.006221","archive":["Portico"],"relation":{},"ISSN":["0196-3635","1939-4640"],"issn-type":[{"value":"0196-3635","type":"print"},{"value":"1939-4640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,8]]}}}